De Nardi, A. B. [UNESP]Daleck, C. R. [UNESP]Amorin, R. L. [UNESP]Huppes, R. R. [UNESP]Uscategui, R. A. R. [UNESP]Rodaski, S.Calderon, C.Neto, R. T. [UNESP]2014-12-032014-12-032013-01-01Archivos De Medicina Veterinaria. Valdivia: Univ Austral Chile, Fac Ciencias Veterinarias, v. 45, n. 3, p. 311-316, 2013.0301-732Xhttp://hdl.handle.net/11449/111230The aim of this study was to detect the expression of ciclooxigenase-2 (COX-2) in metastatic primary carcinoma and non metastatic carcinoma, taking into consideration the relation between COX-2 and the progression of cancer. Evaluation of the COX-2 expression was achieved by immunohistochemistry analysis, using the primary polyclonal antibody anti-PGHS-2, clone PG 27, (Oxford Biomedical Research). The number of marked cells by the COX-2 antibody was higher (P < 0.001) in the metastatic primary carcinoma (81.25%) than non-metastatic (60.3%). There was a positive correlation between the number of labeled cells.311-316spaCancerMammary neoplasmciclooxigenase-2DogArtigo10.4067/S0301-732X2013000300012WOS:000330203700011Acesso abertoWOS000330203700011.pdf